Literature DB >> 21051388

Human γ-herpesviruses Epstein-Barr virus and human herpesvirus-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension.

Séverine Valmary1, Peter Dorfmüller2, David Montani2, Marc Humbert2, Pierre Brousset3, Bruno Degano4.   

Abstract

BACKGROUND: In susceptible individuals, multiple events may trigger pulmonary vascular remodeling and pulmonary arterial hypertension (PAH). Human herpesvirus-8 (HHV-8), a γ-herpesvirus homologous with Epstein-Barr virus (EBV), was suggested to act as a "second hit" in the development of PAH in susceptible patients. Although there is indirect evidence from in vitro and animal studies in favor of a link between γ-herpesviruses and the pathophysiology of PAH, results remain controversial. Therefore, we investigated the presence of EBV and HHV-8 in the lungs of patients with PAH.
METHODS: Thirty-four lungs explanted from French patients with end-stage PAH (mean age, 38 ± 14 years; 19 women) were studied. Tissue samples were incorporated into tissue microarrays. Normal lung tissues served as negative controls. Kaposi sarcoma tissue served as a positive control for HHV-8, and EBV-associated lymphoma served as a positive control for EBV. The presence of HHV-8 was investigated with immunohistochemistry and polymerase chain reaction. The presence of EBV was investigated with immunohistochemistry and in situ hybridization.
RESULTS: For HHV-8, none of PAH lung samples showed a "stippling" nuclear pattern classically observed in HHV-8-positive Kaposi sarcoma lesions. When studied by polymerase chain reaction, all cases remained negative. For EBV, none of the PAH lung samples showed positive staining, whatever the technique applied.
CONCLUSIONS: HHV-8 and EBV cannot be detected in the lungs of patients with end-stage PAH. The role of these γ-herpesviruses in the pathophysiology of PAH is, therefore, unlikely.

Entities:  

Mesh:

Year:  2010        PMID: 21051388     DOI: 10.1378/chest.10-1200

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Toshie Saito; Kazuya Miyagawa; Shih-Yu Chen; Rasa Tamosiuniene; Lingli Wang; Orr Sharpe; Erik Samayoa; Daisuke Harada; Jan-Renier A J Moonen; Aiqin Cao; Pin-I Chen; Jan K Hennigs; Mingxia Gu; Caiyun G Li; Ryan D Leib; Dan Li; Christopher M Adams; Patricia A Del Rosario; Matthew Bill; Francois Haddad; Jose G Montoya; William H Robinson; Wendy J Fantl; Garry P Nolan; Roham T Zamanian; Mark R Nicolls; Charles Y Chiu; Maria E Ariza; Marlene Rabinovitch
Journal:  Circulation       Date:  2017-09-21       Impact factor: 29.690

Review 2.  The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension.

Authors:  Nada Kherbeck; Mathieu C Tamby; Guillaume Bussone; Hanadi Dib; Frederic Perros; Marc Humbert; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

3.  Pulmonary veno-occlusive disease: the role of CT.

Authors:  Giangaspare Mineo; Domenico Attinà; Martina Mughetti; Caterina Balacchi; Fiorella De Luca; Fabio Niro; Federica Ciccarese; Luigi Lovato; Vincenzo Russo; Francesco Buia; Cecilia Modolon; Alessandra Manes; Massimiliano Palazzini; Nazareno Galiè; Maurizio Zompatori
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

4.  Overexpression of PD-1 on Peripheral Blood Lymphocytes in Patients with Idiopathic Pulmonary Arterial Hypertension and Its Association with High Viral Loads of Epstein-Barr Virus and Poor Clinical Parameters.

Authors:  Michał Tomaszewski; Ewelina Grywalska; Andrzej Tomaszewski; Piotr Błaszczak; Marcin Kurzyna; Jacek Roliński; Grzegorz Kopeć
Journal:  J Clin Med       Date:  2020-06-24       Impact factor: 4.241

Review 5.  Novel insights on the pulmonary vascular consequences of COVID-19.

Authors:  François Potus; Vicky Mai; Marius Lebret; Simon Malenfant; Emilie Breton-Gagnon; Annie C Lajoie; Olivier Boucherat; Sébastien Bonnet; Steeve Provencher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-06-17       Impact factor: 5.464

6.  Human immunodeficiency virus, herpes virus infections, and pulmonary vascular disease.

Authors:  Sonia C Flores; Sharilyn Almodovar
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

Review 7.  Noninfectious pulmonary complications of human immunodeficiency virus infection.

Authors:  Bashar Staitieh; David M Guidot
Journal:  Am J Med Sci       Date:  2014-12       Impact factor: 2.378

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.